AU2017340594B2 - Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid - Google Patents

Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid Download PDF

Info

Publication number
AU2017340594B2
AU2017340594B2 AU2017340594A AU2017340594A AU2017340594B2 AU 2017340594 B2 AU2017340594 B2 AU 2017340594B2 AU 2017340594 A AU2017340594 A AU 2017340594A AU 2017340594 A AU2017340594 A AU 2017340594A AU 2017340594 B2 AU2017340594 B2 AU 2017340594B2
Authority
AU
Australia
Prior art keywords
composition
component
pharmaceutically acceptable
arundic acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017340594A
Other languages
English (en)
Other versions
AU2017340594A1 (en
Inventor
Narito Tateishi
Michio Yamamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brivention Pharmaceutical Shanghai Inc
Original Assignee
Brivention Pharmaceutical Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brivention Pharmaceutical Shanghai Inc filed Critical Brivention Pharmaceutical Shanghai Inc
Publication of AU2017340594A1 publication Critical patent/AU2017340594A1/en
Application granted granted Critical
Publication of AU2017340594B2 publication Critical patent/AU2017340594B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2017340594A 2016-10-03 2017-09-27 Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid Ceased AU2017340594B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2016-195505 2016-10-03
JP2016195505 2016-10-03
JP2017-184731 2017-09-26
JP2017184731 2017-09-26
PCT/JP2017/034926 WO2018066427A1 (ja) 2016-10-03 2017-09-27 Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Publications (2)

Publication Number Publication Date
AU2017340594A1 AU2017340594A1 (en) 2019-04-18
AU2017340594B2 true AU2017340594B2 (en) 2020-09-10

Family

ID=61832036

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017340594A Ceased AU2017340594B2 (en) 2016-10-03 2017-09-27 Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid

Country Status (16)

Country Link
US (1) US10828303B2 (enExample)
EP (1) EP3520795B1 (enExample)
JP (2) JP6596697B2 (enExample)
KR (1) KR20190065315A (enExample)
CN (2) CN110267661B (enExample)
AU (1) AU2017340594B2 (enExample)
BR (1) BR112019006429A2 (enExample)
CA (1) CA3039027A1 (enExample)
CO (1) CO2019003255A2 (enExample)
IL (1) IL265688A (enExample)
MX (1) MX2019003837A (enExample)
PH (1) PH12019500636A1 (enExample)
SG (1) SG11201902599SA (enExample)
TW (1) TW201818939A (enExample)
WO (1) WO2018066427A1 (enExample)
ZA (1) ZA201902341B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907591D0 (en) * 2019-05-29 2019-07-10 Eolas Res Limited Composition and use
IT202000015895A1 (it) 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234029A (ja) * 1985-12-27 1987-10-14 Tanabe Seiyaku Co Ltd 中枢神経賦活剤
WO2005105722A1 (ja) * 2004-04-28 2005-11-10 Ono Pharmaceutical Co., Ltd. (２ｒ)−２−プロピルオクタン酸とアミンとからなる結晶
JP2006143708A (ja) * 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6223429A (ja) * 1985-07-24 1987-01-31 Ishikawajima Harima Heavy Ind Co Ltd 水素同位体の回収・貯蔵・供給装置
DK0632008T3 (da) 1993-06-01 1998-09-23 Ono Pharmaceutical Co Pentansyrederivater
JPH0782166A (ja) 1993-09-14 1995-03-28 Tanabe Seiyaku Co Ltd 抗ショック剤
US9016221B2 (en) * 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
TW202436282A (zh) * 2008-05-19 2024-09-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
PL2443120T3 (pl) * 2009-06-16 2017-04-28 Rspr Pharma Ab Krystaliczna postać pemirolastu
CN102786414B (zh) * 2012-08-15 2014-07-16 四川大学 一类用于治疗和/或预防神经退行性相关疾病的化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234029A (ja) * 1985-12-27 1987-10-14 Tanabe Seiyaku Co Ltd 中枢神経賦活剤
WO2005105722A1 (ja) * 2004-04-28 2005-11-10 Ono Pharmaceutical Co., Ltd. (２ｒ)−２−プロピルオクタン酸とアミンとからなる結晶
JP2006143708A (ja) * 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KWON, MYOUNG-OK et al., "List of drugs in development for neurodegenerative diseases", Neurodegenerative Dis, (2004), vol. 1, doi:10.1159/000081242, ISSN 1660-2854, pages 113 - 152 *

Also Published As

Publication number Publication date
NZ752311A (en) 2020-12-18
EP3520795A1 (en) 2019-08-07
JP6596697B2 (ja) 2019-10-30
CN113559102A (zh) 2021-10-29
JPWO2018066427A1 (ja) 2019-07-25
KR20190065315A (ko) 2019-06-11
BR112019006429A2 (pt) 2019-06-25
US20190240221A1 (en) 2019-08-08
WO2018066427A1 (ja) 2018-04-12
AU2017340594A1 (en) 2019-04-18
CN110267661A (zh) 2019-09-20
MX2019003837A (es) 2019-06-24
JP2019203007A (ja) 2019-11-28
CA3039027A1 (en) 2018-04-12
CO2019003255A2 (es) 2019-04-12
ZA201902341B (en) 2020-08-26
SG11201902599SA (en) 2019-05-30
TW201818939A (zh) 2018-06-01
CN110267661B (zh) 2021-08-03
IL265688A (en) 2019-05-30
CN113559102B (zh) 2023-01-03
US10828303B2 (en) 2020-11-10
PH12019500636A1 (en) 2019-10-28
EP3520795B1 (en) 2023-06-14
EP3520795A4 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
ES2587978T3 (es) Forma cristalina de (s)-4-hidroxi-2-oxo-1-pirrolidina acetamida, método de preparación y uso de la misma
KR102563378B1 (ko) 2-(1-아실옥시-n-펜틸)벤조산 및 염기성 아미노산 또는 아미노구아니딘이 형성하는 염, 이의 제조 방법 및 용도
JP2016511273A (ja) Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型
AU2017340594B2 (en) Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
CN108239095A (zh) 一类吡喃并咔唑生物碱及其制备方法和其药物组合物与用途
RU2537847C2 (ru) Новые фумаратные соли антагониста гистаминового рецептора н3
KR20240154068A (ko) P2x3 억제제 화합물 및 이의 염, 다형체 및 용도
JP5888612B2 (ja) 縮合ピリジン化合物塩の結晶
NZ752311B2 (en) Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
HK40005518A (en) Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
CN113185447B (zh) 邻苯二甲酰半胱酰胺类化合物、其制备方法和用途
KR102509190B1 (ko) 트리메부틴 말레산염의 다형체 및 이의 사용방법
TWI885324B (zh) 環己烯酮化合物之結晶形
TWI665188B (zh) Ｎ－［２－（６－氟－１ｈ－吲哚－３－基）乙基］－３－（２，２，３，３－四氟丙氧基）苄胺鹽酸鹽之新穎多晶型形式
ES2954408T3 (es) Inhibidor de colinesterasa polimorfo y aplicación de este
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
BR102023008236A2 (pt) Forma sólida cristalina à base de hidralazina e furosemida, composição farmacêutica, kit e uso relacionado
KR20060118375A (ko) (±)2-(디메틸아미노)-1-｛[Ｏ-(ｍ-메톡시페네틸)페녹시]메틸｝에틸 수소 숙시네이트 염산염의 결정
JPWO2003087091A1 (ja) キノキサリンジオン誘導体無水物の新規結晶
CN119954776A (zh) 一种法舒地尔二氯乙酸盐的制备方法和应用
HK40028824A (en) Polymorphic forms of trimebutine maleate and method of using same
WO2016055607A1 (en) Benzothiazole derivative useful in the treatment of chagas disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired